OverviewSuggest Edit

KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. Its primary efforts include the development of safer, abuse resistant opioid pain relievers. KemPharm’s drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. The Company uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
TypePublic
Founded2006
HQKissimmee, US
Websitekempharm.com
Employee Ratings0

Latest Updates

Employees (est.) (Feb 2019)32
Share Price (Mar 2019)$2 (-1%)

Key People/Management at KemPharm

Travis C. Mickle

Travis C. Mickle

President, Chief Executive Officer and Chairman of the Board; Co-Founder
Christal M.m. Mickle

Christal M.m. Mickle

Vice President, Operations and Product Development; Co-Founder
Andrew Barrett

Andrew Barrett

Vice President, Scientific Affairs
Rene A. Braeckman

Rene A. Braeckman

Vice President, Clinical Development
Christopher M. Lauderback

Christopher M. Lauderback

Vice President, Manufacturing
Show more

KemPharm Office Locations

KemPharm has an office in Kissimmee
Kissimmee, US (HQ)
1180 Celebration Blvd
Show all (1)
Report incorrect company information

KemPharm Financials and Metrics

KemPharm Revenue

USD

Net income (FY, 2018)

(56.5m)

EBIT (FY, 2018)

(55.9m)

Market capitalization (15-Mar-2019)

54.0m

Closing stock price (15-Mar-2019)

2.0

Cash (31-Dec-2018)

18.4m
KemPharm's current market capitalization is $54 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

8.9m14.0m12.8m12.5m

R&D expense

13.9m20.5m20.6m41.8m

Operating expense total

22.8m37.5m33.4m55.9m

EBIT

(22.8m)(37.5m)(33.4m)(55.9m)
Quarterly
USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

3.2m3.7m4.3m3.1m3.3m3.3m3.1m3.4m

R&D expense

2.8m3.2m5.0m4.3m4.1m6.3m11.6m10.5m

Operating expense total

6.0m7.0m9.3m10.4m7.4m9.6m14.8m13.9m

EBIT

(6.0m)(7.0m)(9.3m)(10.4m)(7.4m)(9.6m)(14.8m)(13.9m)
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

32.3m16.8m10.9m18.4m

Inventories

2.8m489.0k

Current Assets

54.1m74.4m47.0m23.7m

PP&E

403.0k2.0m2.0m1.8m
Quarterly
USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

64.2m77.3m27.5m20.8m12.9m7.8m8.8m16.5m

Inventories

1.4m

Current Assets

64.8m111.4m84.6m65.3m63.0m50.2m39.1m30.9m

PP&E

352.0k443.0k1.1m1.5m2.2m2.1m1.9m1.8m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(54.7m)(16.5m)(43.4m)(56.5m)

Depreciation and Amortization

84.0k175.0k336.0k324.0k

Inventories

(1.2m)(15.9m)

Accounts Payable

1.3m1.1m(801.0k)(1.6m)
Quarterly
USDQ1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

1.4m

Accounts Payable

4.0m4.9m4.2m5.4m5.6m4.6m6.3m6.4m
USDY, 2018

Financial Leverage

-0.4 x
Show all financial metrics
Report incorrect company information

KemPharm Online and Social Media Presence

Embed Graph
Report incorrect company information

KemPharm News and Updates

KemPharm Provides Update on APADAZ® Formulary Adoption

Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET

KemPharm to Present at Upcoming Investor Conferences

CELEBRATION, Fla., March 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that management will present at several investor conferences during March 2019.

KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate

Patents Extend Across KemPharm’s Prodrug Portfolio, Including IP Protection for KP415 in Canada, Japan and Korea

KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting

Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415

KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

APADAZ® Now Approved in Three Dosage Strengths, Providing Greater Flexibility to Prescribers Through Additional Dosing Options

KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio

CELEBRATION, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a corporate update on the ongoing partnering process for its co-lead clinical development product …
Show more
Report incorrect company information

KemPharm Blogs

KemPharm Reports Q4 and FY 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Completed KP415 clinical and human abuse potential programs Received approval of APADAZ® Enhanced pipeline with the addition of KP879, a potential new treatment…

KemPharm to Report Fourth Quarter and Year End 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, February 28, 2019, 4:30 p.m. ET Celebration, FL – February 21, 2019 –KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announc…

KemPharm Presenting Four Scientific Posters at APSARD’s 2019 Annual Meeting

Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415 Intranasal HAP data selected to be presented during oral “data blitz session” Celebration, FL – January 18, 2019 –KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in th…

KemPharm Webcast on VirtualInvestorConferences.com Now Available for On-Demand Viewing

CELEBRATION, FL, December 11, 2018 /PRNewswire/ —KemPharm, Inc.(NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D.,presented at an interactive online investor conference. …

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder Content Import Tue, 11/13/2018 - 07:33 KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder November 13, 2018 at…

KemPharm, Inc. Reports Third Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01 efficacy and safety trial in children with attention deficit hyperactivity disorder (ADHD) Announced positive topline results f…
Show more

KemPharm Frequently Asked Questions

  • When was KemPharm founded?

    KemPharm was founded in 2006.

  • Who are KemPharm key executives?

    KemPharm's key executives are Travis C. Mickle, Christal M.m. Mickle and Andrew Barrett.

  • How many employees does KemPharm have?

    KemPharm has 32 employees.

  • Who are KemPharm competitors?

    Competitors of KemPharm include Mitra Biotech, Adaptive Biotechnologies and F-star Biotechnology.

  • Where is KemPharm headquarters?

    KemPharm headquarters is located at 1180 Celebration Blvd, Kissimmee.

  • Where are KemPharm offices?

    KemPharm has an office in Kissimmee.

  • How many offices does KemPharm have?

    KemPharm has 1 office.